- Feed Type
- Company Name
- Mailing Address
3 Highwood Drive Tewksbury, MA 01876
- Company Description
We are currently developing an innovative, catheter-based mitral valve repair system that not only provides an alternative to open heart surgery but emulates the traditional surgical repair technique.
The condition treated, mitral valve regurgitation (MR), is common in patients with Congestive Heart Failure. Clinical studies have proven that MR significantly increases the risk of mortality in patients afflicted with CHF, a disease affecting 25 Million worldwide. Studies hence recommend earlier treatment of MR in these patients.
- Transaction Type
- Transaction Amount
- Transaction Round
- Proceeds Purposes
Mitralign will use the credit facility for working capital as the company advances development of its mitral valve repair device.
- M&A Terms
- Venture Investor
GE Healthare Financial Services